ORLANDO, FL – BeneCard PBF earned the highest client satisfaction rating in 39 of the 42 categories in the 2015 Pharmacy Benefit Management Institute (PBMI) PBM Customer Satisfaction Survey. The survey, conducted annually, compares all of the top PBMs in the country.
“This is a great validation of how the BeneCard PBF model can provide clients with more of what they want,” said Ken Ullman, chairman of the board of directors. “It’s also a great message to the marketplace that BeneCard PBF is now a tested and proven alternative.”
BeneCard PBF offers full pass-through pricing and transparency with a “High Touch” service model. Two of the categories in which BeneCard PBF led the industry were “delivering promised savings” and “delivering promised services.” This is now the second year in a row that BeneCard PBF has been rated “most likely to be recommended” in the PBMI survey.
Michael Perry, president of BeneCard PBF said, “It’s our employees who deserve the accolades. The BeneCard PBF team always puts members and clients first. When you do that and focus on your clients’ goals, there is no limit to what can be achieved.”
As part of its mission to study best practices and drive process improvement, PBMI has conducted the annual pharmacy benefit manager (PBM) customer satisfaction survey for nearly two decades. The PBMI survey has since become the trusted benchmark of the PBM marketplace. The PBMI survey was completed in January 2015 by 421 U.S. plan sponsors, representing more than 96.6 million members. BeneCard PBF was compared with other pharmacy benefit managers with 20 million or fewer members. In an unparalleled performance, BeneCard PBF received the highest scores in the 39 categories of any PBM, regardless of size.
“The PBMI results demonstrate the direct link between transparency, delivery of promised savings, and client satisfaction,” observed Robert Cascarano, executive vice president of BeneCard PBF. “We are proud to serve each of our clients and appreciate their support.”
About BeneCard PBF
BeneCard PBF has locations in Florida, Pennsylvania and New Jersey focused on administering fixed-rate and self-funded prescription benefit programs. BeneCard PBF’s goal is to improve patient health by aligning the mutual interests of payers, pharmacies and providers.
The Pharmacy Benefit Management Institute (PBMI) provides research and education to help health care benefit executives work with pharmacy benefit managers to improve the design and management of drug benefit programs.
June 10, 2015, AstraZeneca voluntarily recalled Nexium (esomeprazole magnesium) delayed release 20mg capsules. The Class II recall was prompted as a result of a retail pharmacist finding Seroquel (atypical antipsychotic quetiapine fumarate) in an unopened bottle of what should have been Nexium.
The recalled bottles are labeled Lot #FC0064 with an expiration date of May 2017. This lot contains 34,524 bottles of Nexium being recalled.
For those members that have this product, it is suggested that they contact their pharmacy.
For those members who use mail order, Benecard Central Fill has not dispensed any recalled lots of Nexium.
No adverse health reactions have been associated with this recall. If you have any questions about this recall please contact your local retail pharmacist or speak to your doctor.
Adverse events that may be related to the use of this product may also be reported to the United States Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting Program either online, by regular mail or by fax:
Regular Mail: use postage-paid FDA form 3500 available at: www.fda.gov/MedWatch/getforms.htm. Mail the form to: MedWatch, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787
On January 30, 2015, the U.S. Food and Drug Administration (FDA) approved a new formulation for all strengths of Zohydro ER, the single-agent, extended-release hydrocodone product, which is a schedule II controlled substance. Zohydro ER, manufactured by Zogenix, is indicated to treat severe chronic pain that needs continuous treatment and that has not been relieved by previous therapy options.
The new form is considered ‘abuse resistant’ and it is made with a proprietary technology called BeadTek. BeadTek creates thick, sticky goo if the capsules are opened or crushed and the specifies abuse resistance, however, Zogenix, is planning to provide the FDA with results of studies showing that the new formulation is difficult to abuse.
The first FDA approved version of Zohydro ER was approved in October 2013 without any abuse deterrents and will be phased out and replaced with the new form during the second quarter of 2015.
July 7, 2015, The U.S. Food and Drug Administration announced a recall of Lutera (ethinyl estradiol/levonorgestrel) manufactured by Watson/Actavis. The Class III recall was prompted only as a result of incorrect or missing package inserts and no adverse health reactions have been associated with this recall.
The voluntary recall of this birth control impacts 511,283 boxes from the following lots:
KPPY – Expiration date of June 2015
NBXD, NBXF – Expiration date of October 2016
NBXG – Expiration date of September 2015
NKZS – Expiration date of November 2015
NMPT, NNXB, NNWG – Expiration date of January 2016
NMPV, NVWN, NVWP – Expiration date of February 2016
NMTP, NNXC – Expiration date of March 2016
NMWC, NNXH – Expiration date of April 2016
PFHT, PFHW, PFHX – Expiration date of June 2016
PKHH, PKHN, PKHS, PKHT, PPGG, PPGH, PVSZ – Expiration date of August 2016
PYDX – Expiration date of September 2016
For those members that have this product or any questions about the recall, it is suggested that they contact their pharmacy.
Par Pharmaceutical Companies, Inc. announced that the US Food and Drug Administration (FDA) approved the AB-rated generic version of Exforge (amlodipine/valsartan). Brand Exforge is manufactured by Novartis. Exforge is used for the treatment of high blood pressure.
The generic of Exforge will be available in all current dosage strengths including 5mg/160mg, 10mg/160mg, 5mg/320mg and 10mg/320 mg tablets. Par Pharmaceutical Companies, Inc. was also granted 180 days exclusivity before any other new generics can be approved by the FDA. According to IMS health, Exforge saw annual sales of approximately $422 million.
June 24, 2015, The U.S. Food and Drug Administration (FDA) issued a warning to patients and their prescribers regarding skin color loss as a result of the Daytrana Patch (methylphenidate transdermal system). A new warning label is now required by the FDA to inform patients about chemical leukoderma, which is a skin condition that may be caused by this medication.
The Daytrana Patch is used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD), to increase attention and decrease restlessness in children and adolescents who are overactive, cannot concentrate for extended periods of time, or are easily distracted and impulsive.
Chemical leukoderma is the discoloring of the skin due to repeated exposure to certain chemicals. The discoloring of the skin is not harmful, however it can cause emotional distress and it is not known whether chemical leukoderma is reversible. The area of skin that may lose color can range in size up to about 8 inches in diameter.
Patients using the Daytrana patch should not stop their medication without first talking to their prescriber and should watch for areas of lighter skin developing, especially under the drug patch. If any indication of skin color loss is noticed, patients should contact their prescriber immediately to report the changes. The FDA recommends that health care professionals consider alternative treatments for patients who experience these skin color changes.